Biomarkers and Targeted Therapy in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers. PDAC is a complex and devastating disease with only 1%–3% survival rate in five years after the second stage. Treatment of PDAC is complicated due to the tumor microenvironment, changing cell behaviors to the mesenchymal...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847554/ |
| id |
pubmed-4847554 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-48475542016-05-04 Biomarkers and Targeted Therapy in Pancreatic Cancer Karandish, Fataneh Mallik, Sanku Review Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers. PDAC is a complex and devastating disease with only 1%–3% survival rate in five years after the second stage. Treatment of PDAC is complicated due to the tumor microenvironment, changing cell behaviors to the mesenchymal type, altered drug delivery, and drug resistance. Considering that pancreatic cancer shows early invasion and metastasis, critical research is needed to explore different aspects of the disease, such as elaboration of biomarkers, specific signaling pathways, and gene aberration. In this review, we highlight the biomarkers, the fundamental signaling pathways, and their importance in targeted drug delivery for pancreatic cancers. Libertas Academica 2016-04-26 /pmc/articles/PMC4847554/ /pubmed/27147897 http://dx.doi.org/10.4137/BiC.s34414 Text en © 2016 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Karandish, Fataneh Mallik, Sanku |
| spellingShingle |
Karandish, Fataneh Mallik, Sanku Biomarkers and Targeted Therapy in Pancreatic Cancer |
| author_facet |
Karandish, Fataneh Mallik, Sanku |
| author_sort |
Karandish, Fataneh |
| title |
Biomarkers and Targeted Therapy in Pancreatic Cancer |
| title_short |
Biomarkers and Targeted Therapy in Pancreatic Cancer |
| title_full |
Biomarkers and Targeted Therapy in Pancreatic Cancer |
| title_fullStr |
Biomarkers and Targeted Therapy in Pancreatic Cancer |
| title_full_unstemmed |
Biomarkers and Targeted Therapy in Pancreatic Cancer |
| title_sort |
biomarkers and targeted therapy in pancreatic cancer |
| description |
Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers. PDAC is a complex and devastating disease with only 1%–3% survival rate in five years after the second stage. Treatment of PDAC is complicated due to the tumor microenvironment, changing cell behaviors to the mesenchymal type, altered drug delivery, and drug resistance. Considering that pancreatic cancer shows early invasion and metastasis, critical research is needed to explore different aspects of the disease, such as elaboration of biomarkers, specific signaling pathways, and gene aberration. In this review, we highlight the biomarkers, the fundamental signaling pathways, and their importance in targeted drug delivery for pancreatic cancers. |
| publisher |
Libertas Academica |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847554/ |
| _version_ |
1613571927646928896 |